Cargando…

The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer

This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial r...

Descripción completa

Detalles Bibliográficos
Autores principales: Bragina, O. D., Deyev, S. M., Chernov, V. I., Tolmachev, V. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: A.I. Gordeyev 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307982/
https://www.ncbi.nlm.nih.gov/pubmed/35923562
http://dx.doi.org/10.32607/actanaturae.11611
_version_ 1784752885521711104
author Bragina, O. D.
Deyev, S. M.
Chernov, V. I.
Tolmachev, V. M.
author_facet Bragina, O. D.
Deyev, S. M.
Chernov, V. I.
Tolmachev, V. M.
author_sort Bragina, O. D.
collection PubMed
description This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction.
format Online
Article
Text
id pubmed-9307982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher A.I. Gordeyev
record_format MEDLINE/PubMed
spelling pubmed-93079822022-08-02 The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer Bragina, O. D. Deyev, S. M. Chernov, V. I. Tolmachev, V. M. Acta Naturae Research Article This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction. A.I. Gordeyev 2022 /pmc/articles/PMC9307982/ /pubmed/35923562 http://dx.doi.org/10.32607/actanaturae.11611 Text en Copyright ® 2022 National Research University Higher School of Economics. https://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bragina, O. D.
Deyev, S. M.
Chernov, V. I.
Tolmachev, V. M.
The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
title The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
title_full The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
title_fullStr The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
title_full_unstemmed The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
title_short The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
title_sort evolution of targeted radionuclide diagnosis of her2-positive breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307982/
https://www.ncbi.nlm.nih.gov/pubmed/35923562
http://dx.doi.org/10.32607/actanaturae.11611
work_keys_str_mv AT braginaod theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer
AT deyevsm theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer
AT chernovvi theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer
AT tolmachevvm theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer
AT braginaod evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer
AT deyevsm evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer
AT chernovvi evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer
AT tolmachevvm evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer